This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Monday, February 25, 2013
Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis
Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis
Li-Xuan Sang, Bing Chang, Xiao-Hang Li and Min Jiang
BMC Gastroenterology 2013, 13:34 doi:10.1186/1471-230X-13-34 Published: 25 February 2013
Abstract (provisional)
Full Text - provisional PDF
Background
Epidemiologic studies have reported inconsistent results regarding coffee consumption and the risk of liver cancer. We performed a meta-analysis of published case--control and cohort studies to investigate the association between coffee consumption and liver cancer.
Methods
We searched Medline, EMBASE, ISI Web of Science and the Cochrane library for studies published up to May 2012. We performed a meta-analysis of nine case--control studies and seven cohort studies.
Results
The summary odds ratio (OR) for high vs no/almost never drinkers was 0.50 (95% confidence interval (CI): 0.42--0.59), with no significant heterogeneity across studies (Q = 16.71; P = 0.337; I2 = 10.2%). The ORs were 0.50 (95% CI: 0.40--0.63) for case--control studies and 0.48 (95% CI: 0.38--0.62) for cohort studies. The OR was 0.38 (95% CI: 0.25--0.56) in males and 0.60 (95% CI: 0.33--1.10) in females. The OR was 0.45 (95% CI: 0.36--0.56) in Asian studies and 0.57 (95% CI: 0.44--0.75) in European studies. The OR was 0.39 (95% CI: 0.28--0.54) with no adjustment for a history of liver disease and 0.54 (95% CI: 0.46--0.66) after adjustment for a history of liver disease.
Conclusions
The results of this meta-analysis suggested an inverse association between coffee consumption and liver cancer. Because of the small number of studies, further prospective studies are needed.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment